Dr Wilbert Bannenberg speaks to ecancer about equitable access to affordable essential oncology medicines in low- and middle-income countries.

He talks about the problem of excessive pricing of cancer medicines and how prevalent it is.

He also discusses the Fair Pharma Scorecard and whether it can be used in the context of cancer medicines.

Dr Bannenberg also highlights the importance and the obstacles to equitable cancer care in LMICs.

He concludes by sharing some success stories of how certain essential medicines were made affordable.